A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs Erlotinib (Primary) ; Sirolimus (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Adverse reactions; Therapeutic Use
- 17 Dec 2018 Status changed from active, no longer recruiting to discontinued due to low accural.
- 31 Aug 2018 Biomarkers information updated
- 31 Jan 2018 Planned End Date changed from 1 Jan 2020 to 1 Jan 2019.